tirzepatide surmount 2 once weekly for the treatment of obesity in people with type diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Surmount Program. TZP, Tirzepatide; – surmount-1 trial tirzepatide obesity without

Bcl-xL overexpression attenuates glutathione depletion in FL5.12 cells following interleukin-3 withdrawal

Abstract GLP-1 receptor agonists represent a breakthrough for managing type-2 diabetes and obesity, offering metabolic benefits across multiple organ systems

Abstract Obesity in women of reproductive age has a number of adverse metabolic effects, including Type II Diabetes (T2D), dyslipidemia, and cardiovascular disease

What we know so far: A 2025 study followed 139,002 older adults with diabetes

Taylor shares her deeply personal and inspiring storyone that began with her own health collapse, transformed through functional medicine, and took a dramatic turn when she was unexpectedly diagnosed with a brain tumor